Gonadorelin
WellnessAlso known as: GnRH, Gonadotropin-Releasing Hormone, LHRH, Factrel, Lutrepulse
Limited EvidenceWhat is Gonadorelin?
The synthetic form of the hypothalamus's own gonadotropin-releasing hormone, with a genuinely long clinical history: it was FDA-approved for decades as Factrel (a diagnostic stimulation test) and Lutrepulse (pulsatile pump therapy for ovulation induction and male fertility). Both products have since been discontinued in the US, and gonadorelin is now available only through 503A compounding pharmacies. Its current wave of popularity comes from a different context entirely — as a twice-daily or multi-weekly self-injected adjunct to preserve testicular size and fertility during TRT (testosterone replacement therapy) — and that specific use case runs well ahead of any dedicated trial evidence, resting instead on decades-old pulsatile-pump data and comparisons to hCG that were never designed to test gonadorelin itself.
How it works
Gonadorelin is structurally identical to native GnRH. It binds GnRH receptors on pituitary gonadotroph cells, triggering release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone) — LH drives testosterone production from testicular Leydig cells (or ovulation in women), while FSH drives spermatogenesis via Sertoli cells (or follicular development in women). It has an extremely short plasma half-life, roughly 2 to 8 minutes, because it's rapidly broken down by endopeptidases. That short half-life is the whole point of the classic delivery method: a portable pump (Lutrepulse) delivered discrete IV or subcutaneous pulses roughly every 60–90 minutes, mimicking the hypothalamus's own pulse generator. This is where the dosing-pattern paradox comes in — physiologic, pulsatile stimulation activates the axis, but continuous or high-frequency receptor exposure desensitizes GnRH receptors and shuts the axis down. That isn't theoretical: it's the deliberate, FDA-approved mechanism behind long-acting GnRH agonist drugs (like leuprolide) used for prostate cancer suppression and central precocious puberty, which work by flooding the same receptor continuously. Fixed-interval subcutaneous self-injection, the pattern most TRT-adjunct protocols actually use, sits somewhere in between true pulsatile pump dosing and continuous exposure — and it isn't established which side of that line typical home dosing schedules land on.
What marketers claim
- ▸a safe, natural way to prevent testicular shrinkage and preserve fertility while on TRT
- ▸a cheaper, gentler alternative to hCG with none of the downsides
- ▸keeps natural testosterone production ready to restart so you can come off TRT without a rough recovery
- ▸fully restores HPTA (hypothalamic-pituitary-testicular axis) function during a cycle
- ▸works as a mini testosterone booster on its own
What evidence supports
- ✓FDA-approved for decades as Factrel, the gonadorelin (GnRH) stimulation test: a single 100mcg dose used to differentiate pituitary from hypothalamic causes of hypogonadotropic hypogonadism and delayed puberty by measuring the resulting LH rise
- ✓pulsatile administration via the Lutrepulse infusion pump — delivering IV or subcutaneous pulses roughly every 60–90 minutes — has decades of published trial data inducing puberty in men with isolated GnRH deficiency, restoring ovulatory cycles in women with hypothalamic amenorrhea, and inducing spermatogenesis in men with hypogonadotropic hypogonadism
- ✓a 2024 retrospective study of 28 men with congenital hypogonadotropic hypogonadism who had failed to respond to standard hCG/hMG gonadotropin therapy found that switching to pulsatile GnRH achieved sperm production in 60.7% of patients (median time to spermatogenesis: 12 months) and produced greater testicular volume gains than the regimen they had failed
- ✓the dosing-pattern-dependent mechanism itself is clinically validated technology, not speculation — the same GnRH receptor is deliberately exploited in the opposite direction (continuous exposure to desensitize and suppress) by approved GnRH agonist drugs
Research evidence
Key studies on Gonadorelin, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Clinical review 4: Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men
Finding: Established the clinical framework for gonadorelin as both a diagnostic tool (the GnRH stimulation test) and a treatment via pulsatile administration to restore pituitary gonadotropin secretion in men with isolated GnRH deficiency.
Limitation: A review synthesizing earlier trial and case data, not a standalone controlled study; reflects an era of specialized pump-based delivery, not modern self-injection protocols.
Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone
Finding: Long-term pulsatile low-dose GnRH, delivered via portable infusion pump, successfully induced pubertal development and normalized gonadotropin secretion in men with isolated GnRH deficiency.
Limitation: Very small cohort using continuous IV pump access under close clinical monitoring — not comparable to intermittent subcutaneous self-injection.
Pulsatile gonadotropin releasing hormone therapy for spermatogenesis in congenital hypogonadotropic hypogonadism patients who had poor response to combined gonadotropin therapy
Finding: Among men who had failed roughly a year of standard hCG/hMG gonadotropin therapy, switching to pulsatile GnRH achieved sperm production in 60.7% (17/28), with greater testicular volume gains than the prior regimen.
Limitation: Retrospective design with uncontrolled adherence monitoring; only 28.6% of patients had genetic screening; authors call for a larger prospective randomized study to confirm findings.
Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review
Finding: Describes GnRH-based approaches as biologically rational but constrained by dosing complexity, and explicitly notes that gonadorelin lacks the randomized controlled trial base that exists for hCG in the TRT-fertility-preservation context.
Limitation: A narrative review, not new trial data — its core conclusion is that dedicated evidence for this specific use case does not yet exist.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Within an hour (diagnostic use)
In the GnRH stimulation test, a single dose produces a measurable LH rise within roughly 20–40 minutes, used to distinguish pituitary from hypothalamic causes of hypogonadism.
Weeks to months (pulsatile pump therapy)
Historical trials show induced puberty or restored ovulatory cycles within weeks of starting pulsatile dosing; spermatogenesis outcomes take longer, with a median of about 12 months to achieve sperm production in the 2024 congenital hypogonadotropic hypogonadism cohort.
Days to weeks (continuous or high-frequency exposure)
Receptor desensitization sets in, progressively suppressing LH/FSH release — the same trajectory deliberately exploited by continuous-exposure GnRH agonist drugs for hormonal suppression.
Long-term self-directed TRT-adjunct use
No controlled long-term data exists for the twice-daily or multi-weekly self-injection protocols currently popular in TRT communities — durability of testicular and fertility protection over months to years is unverified.
Safety notes & concerns
Full safety guide →- ⚠no FDA-approved gonadorelin product is currently sold in the US — Factrel and Lutrepulse were both discontinued (Lutrepulse around 2000) — so all current use, including in TRT clinics, relies on 503A-compounded gonadorelin, which does not go through the same premarket safety, purity, and potency review as the original approved products
- ⚠the specific popular use case — subcutaneous self-injection multiple times a week or daily to preserve testicular size and fertility during exogenous testosterone use — has essentially no dedicated randomized trial evidence; a 2026 narrative review of peptide strategies for TRT-induced reproductive suppression describes GnRH-based approaches as limited by dosing complexity and lacking the trial base that exists for hCG
- ⚠the whole rationale depends on truly pulsatile delivery, and fixed-interval subcutaneous self-injection does not verifiably replicate the ~60–90-minute native pulse frequency used in the pump-based trials that generated the positive historical data — there's no confirmation that common home dosing schedules avoid drifting toward the continuous-exposure pattern that desensitizes the receptor instead
- ⚠an extremely short half-life (roughly 2–8 minutes) means reconstitution accuracy and injection timing matter far more than with a longer-acting option like hCG, and dosing errors are more consequential
- ⚠maintaining testicular size and fullness is not the same as maintaining sperm production or fertility — marketing often conflates the two, and gonadorelin's actual effect on semen parameters specifically in men on TRT is not well characterized
- ⚠historical trial data reports headache, nausea, and injection-site reactions; pulsatile pump use in women carries a risk of overstimulating follicular development if not closely monitored
Pairs well with
Use caution with
Frequently asked questions
Is gonadorelin the same as hCG for preserving fertility on TRT?
No, and they work differently. hCG mimics LH directly at the testes, with decades of trial data supporting its use to maintain testicular volume and intratesticular testosterone during TRT. Gonadorelin instead stimulates the pituitary to release both LH and FSH on its own. Gonadorelin's rise in TRT clinics has been driven largely by hCG access, cost, and regulatory issues — not by head-to-head trials showing it works as well. Most fertility-focused clinicians still consider hCG the better-supported option.
If hCG has more evidence, why do so many TRT clinics prescribe gonadorelin instead?
Mostly practical reasons: hCG has faced supply and compounding restrictions in some regions, and gonadorelin is often cheaper and easier to source through compounding pharmacies. That's an access and cost story, not an efficacy story — switching to gonadorelin was not prompted by new data showing it matches hCG's track record.
Does injecting gonadorelin more often work better?
Not necessarily, and it can backfire. Gonadorelin's stimulating effect depends on pulsatile, intermittent receptor exposure. Push the frequency high enough or make the exposure continuous, and the GnRH receptor desensitizes instead — the same mechanism deliberately used by long-acting GnRH agonist drugs to shut the axis down entirely. Nobody has established where typical home self-injection schedules fall on that spectrum.
Is gonadorelin FDA approved?
Not currently. The two historical FDA-approved gonadorelin products, Factrel (diagnostic use) and Lutrepulse (pulsatile pump therapy), have both been discontinued in the US. All present-day use, including in TRT clinics, relies on gonadorelin obtained through 503A compounding pharmacies rather than an FDA-approved commercial product.
What was gonadorelin originally developed and approved for?
Two things: as Factrel, a single diagnostic dose (the GnRH stimulation test) used to tell whether hypogonadism originates in the pituitary or the hypothalamus; and as Lutrepulse, pulsatile pump-delivered therapy to induce ovulation in women with hypothalamic amenorrhea and to induce spermatogenesis and fertility in men with hypogonadotropic hypogonadism. Both are decades-old, clinically supervised uses — quite different from today's self-injected TRT-adjunct protocols.
Related wellness peptides
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
understanding as a cautionary example of peptide marketing vs evidence
Further reading
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Gonadorelin
Last updated: 2026-09-10
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.